1603 related articles for article (PubMed ID: 29444952)
61. In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline.
Zhang Y; Lin X; Bush K
J Antibiot (Tokyo); 2016 Aug; 69(8):600-4. PubMed ID: 27353166
[TBL] [Abstract][Full Text] [Related]
62. Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae.
Thaden JT; Pogue JM; Kaye KS
Virulence; 2017 May; 8(4):403-416. PubMed ID: 27384881
[TBL] [Abstract][Full Text] [Related]
63. Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections.
King M; Heil E; Kuriakose S; Bias T; Huang V; El-Beyrouty C; McCoy D; Hiles J; Richards L; Gardner J; Harrington N; Biason K; Gallagher JC
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483952
[TBL] [Abstract][Full Text] [Related]
64. Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children.
Chiotos K; Hayes M; Gerber JS; Tamma PD
J Pediatric Infect Dis Soc; 2020 Feb; 9(1):56-66. PubMed ID: 31872226
[TBL] [Abstract][Full Text] [Related]
65. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases.
Mushtaq S; Vickers A; Woodford N; Livermore DM
J Antimicrob Chemother; 2017 Jun; 72(6):1688-1695. PubMed ID: 28333319
[TBL] [Abstract][Full Text] [Related]
66. The rapid spread of carbapenem-resistant Enterobacteriaceae.
Potter RF; D'Souza AW; Dantas G
Drug Resist Updat; 2016 Nov; 29():30-46. PubMed ID: 27912842
[TBL] [Abstract][Full Text] [Related]
67. Comparison of Two Phenotypic Algorithms To Detect Carbapenemase-Producing Enterobacteriaceae.
Dortet L; Bernabeu S; Gonzalez C; Naas T
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607010
[TBL] [Abstract][Full Text] [Related]
68. Antimicrobial activity of plazomicin against Enterobacteriaceae-producing carbapenemases from 50 Brazilian medical centers.
Martins AF; Bail L; Ito CAS; da Silva Nogueira K; Dalmolin TV; Martins AS; Rocha JLL; Serio AW; Tuon FF
Diagn Microbiol Infect Dis; 2018 Mar; 90(3):228-232. PubMed ID: 29223516
[TBL] [Abstract][Full Text] [Related]
69. Carbapenemase-producing Enterobacteriaceae.
Doi Y; Paterson DL
Semin Respir Crit Care Med; 2015 Feb; 36(1):74-84. PubMed ID: 25643272
[TBL] [Abstract][Full Text] [Related]
70. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance.
Ku YH; Chen CC; Lee MF; Chuang YC; Tang HJ; Yu WL
J Microbiol Immunol Infect; 2017 Dec; 50(6):931-939. PubMed ID: 28716360
[TBL] [Abstract][Full Text] [Related]
71. In vitro evaluation of meropenem-vaborbactam against clinical CRE isolates at a tertiary care center with low KPC-mediated carbapenem resistance.
Kinn PM; Chen DJ; Gihring TM; Schulz LT; Fox BC; McCreary EK; Lepak AJ
Diagn Microbiol Infect Dis; 2019 Mar; 93(3):258-260. PubMed ID: 30344065
[TBL] [Abstract][Full Text] [Related]
72. Prevalence of carbapenem resistance and carbapenemase production among Enterobacteriaceae isolated from urine in the UK: results of the UK infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-UK).
Woodford N; Xu-McCrae L; Mushtaq S; Wu HHT; Ellington MJ; Lancaster O; Davies F; Donaldson H; Rao GG; Verma A; Wareham DW; Ciesielczuk H; Stone GG; Irani PM; Bracher S; Hawkey PM
J Antimicrob Chemother; 2018 Mar; 73(3):698-702. PubMed ID: 29253163
[TBL] [Abstract][Full Text] [Related]
73. Update on the role of ceftazidime-avibactam in the management of carbapenemase-producing Enterobacterales.
Dietl B; Martínez LM; Calbo E; Garau J
Future Microbiol; 2020 May; 15():473-484. PubMed ID: 32301348
[TBL] [Abstract][Full Text] [Related]
74. Using β-lactam/β-lactamase inhibitors for infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae to slow the emergence of carbapenem-resistant Enterobacteriaceae.
Watkins RR; Deresinski S
Expert Rev Anti Infect Ther; 2017 Oct; 15(10):893-895. PubMed ID: 28914107
[No Abstract] [Full Text] [Related]
75. Retrospective Observational Study from a Chinese Network of the Impact of Combination Therapy versus Monotherapy on Mortality from Carbapenem-Resistant
Wang X; Wang Q; Cao B; Sun S; Zhang Y; Gu B; Li B; Liao K; Zhao F; Jin L; Jin C; Yang C; Pei F; Zhang Z; Wang H
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30348660
[TBL] [Abstract][Full Text] [Related]
76. The β-Lactams Strike Back: Ceftazidime-Avibactam.
Zasowski EJ; Rybak JM; Rybak MJ
Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
[TBL] [Abstract][Full Text] [Related]
77. OXA-427, a new plasmid-borne carbapenem-hydrolysing class D β-lactamase in Enterobacteriaceae.
Bogaerts P; Naas T; Saegeman V; Bonnin RA; Schuermans A; Evrard S; Bouchahrouf W; Jove T; Tande D; de Bolle X; Huang TD; Dortet L; Glupczynski Y
J Antimicrob Chemother; 2017 Sep; 72(9):2469-2477. PubMed ID: 28859446
[TBL] [Abstract][Full Text] [Related]
78. Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control.
Tängdén T; Giske CG
J Intern Med; 2015 May; 277(5):501-12. PubMed ID: 25556628
[TBL] [Abstract][Full Text] [Related]
79. Activity of BAL30072 alone or combined with β-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters.
Mushtaq S; Woodford N; Hope R; Adkin R; Livermore DM
J Antimicrob Chemother; 2013 Jul; 68(7):1601-8. PubMed ID: 23449829
[TBL] [Abstract][Full Text] [Related]
80. Meropenem-vaborbactam for adults with complicated urinary tract and other invasive infections.
Albin OR; Patel TS; Kaye KS
Expert Rev Anti Infect Ther; 2018 Dec; 16(12):865-876. PubMed ID: 30372359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
